Ning Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ning Huang has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Yanxin Ren
Head and Neck Tumor Research Center, Third Affiliated Hospital of Kunming Medical University, Kunming, China
5 shared publications Meng Yang
Head and Neck Tumor Research Center, Third Affiliated Hospital of Kunming Medical University, Kunming, China
3 shared publicationsChao-Cai Zhang
The Department of Pharmacology, School of Basic Medical Sciences, Kunming Medical University, Kunming, People’s Republic of China
2 shared publications- Jie Yang
Kunming Medical University, Third Affiliated Hospital, Kunming, China
2 shared publications - Wei-Ze Sun
Kunming Medical University, Third Affiliated Hospital, Kunming, China
2 shared publications - Xi-Fang Wu
Third Affiliated Hospital of Kunming Medical University, Head and Neck Surgery Department, Kunming, Yunnan, China
2 shared publications
Latest Publications
- Open Access
- 25 March 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Study on the mechanism of demethoxycurcumin inhibiting immune escape in nasopharyngeal carcinoma
- 25 March 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Open AccessStudy on the mechanism of demethoxycurcumin inhibiting immune escape in nasopharyngeal carcinoma
- Open Access
- 18 February 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-14
Viral IL-10 can promote the proliferation, migration and invasion of nasopharyngeal carcinoma cells and inhibit their apoptosis
Purpose Nasopharyngeal carcinoma is a common clinical malignant tumour in the nasopharynx. The secretion of vIL-10 by EB virus can promote the development of nasopharyngeal carcinoma. The purpose of this study was to provide a theoretical basis for potential targets and mechanisms of vIL-10 in nasopharyngeal carcinoma. Methods A total of 100 ng/mL vIL-10 was applied to the nasopharyngeal carcinoma CNE-2 cell line for 48 h, and then whole transcriptome sequencing analysis was performed to identify potential targets and signalling pathways of vIL-10 in nasopharyngeal carcinoma. The effects of vIL-10 on the proliferation, migration, invasion and apoptosis of human nasopharyngeal carcinoma cells were determined by ELISA, Ki67 immunofluorescence, colony formation, transwell migration/invasion, Hoechst 33,258 staining, flow cytometry and other experiments, and the potential effects of vIL-10 on nasopharyngeal carcinoma cells were verified at the cellular level. Western blotting was performed to measure the changes in key factors of the JAK1-STAT3 signalling pathway in nasopharyngeal carcinoma cells after vIL-10 treatment. Results The whole transcriptome gene sequencing results showed that vIL-10 could effectively activate the JAK-STAT signalling pathway and upregulate the expression of JAK1 and STAT3. Moreover, vIL-10 inhibited the apoptosis of nasopharyngeal carcinoma cells, enhanced their migration and invasion capabilities, and further promoted the proliferation of nasopharyngeal carcinoma cells. Conclusion vIL-10 regulates the JAK1-STAT3 signalling pathway, promotes the proliferation of NPC cells, enhances their migration and invasion capabilities, inhibits tumour cell apoptosis, and participates in the progression of nasopharyngeal carcinoma.
- 18 February 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-14
Open AccessViral IL-10 can promote the proliferation, migration and invasion of nasopharyngeal carcinoma cells and inhibit their apoptosis
Purpose Nasopharyngeal carcinoma is a common clinical malignant tumour in the nasopharynx. The secretion of vIL-10 by EB virus can promote the development of nasopharyngeal carcinoma. The purpose of this study was to provide a theoretical basis for potential targets and mechanisms of vIL-10 in nasopharyngeal carcinoma. Methods A total of 100 ng/mL vIL-10 was applied to the nasopharyngeal carcinoma CNE-2 cell line for 48 h, and then whole transcriptome sequencing analysis was performed to identify potential targets and signalling pathways of vIL-10 in nasopharyngeal carcinoma. The effects of vIL-10 on the proliferation, migration, invasion and apoptosis of human nasopharyngeal carcinoma cells were determined by ELISA, Ki67 immunofluorescence, colony formation, transwell migration/invasion, Hoechst 33,258 staining, flow cytometry and other experiments, and the potential effects of vIL-10 on nasopharyngeal carcinoma cells were verified at the cellular level. Western blotting was performed to measure the changes in key factors of the JAK1-STAT3 signalling pathway in nasopharyngeal carcinoma cells after vIL-10 treatment. Results The whole transcriptome gene sequencing results showed that vIL-10 could effectively activate the JAK-STAT signalling pathway and upregulate the expression of JAK1 and STAT3. Moreover, vIL-10 inhibited the apoptosis of nasopharyngeal carcinoma cells, enhanced their migration and invasion capabilities, and further promoted the proliferation of nasopharyngeal carcinoma cells. Conclusion vIL-10 regulates the JAK1-STAT3 signalling pathway, promotes the proliferation of NPC cells, enhances their migration and invasion capabilities, inhibits tumour cell apoptosis, and participates in the progression of nasopharyngeal carcinoma.
- Open Access
- 1 January 2025
- Published by ScopeMed in Medicine Science | International Medical Journal
- Vol. 14 (1) , 300
Efficacy and safety of immunotherapy for nasopharyngeal carcinoma: A systematic review and meta-analysis
Cancer immunotherapy represents a more advanced and effective treatment modality compared to traditional therapies, playing a significant role in the management of patients with nasopharyngeal carcinoma. However, the efficacy of immunotherapy can be influenced by the 'double-edged sword' nature of the immune system and the individual differences among cancer patients. To assess the efficacy and safety of immunotherapy in patients with nasopharyngeal carcinoma, we conducted a systematic review and meta-analysis of published clinical studies. Clinical research literature related to nasopharyngeal carcinoma immunotherapy was searched in the PubMed, Web of Science, Embase, and Cochrane databases up until December 2010. The literature was screened rigorously according to predefined inclusion and exclusion criteria. Quality evaluation of the included studies was conducted using the Newcastle-Ottawa Scale (NOS), and studies meeting the inclusion criteria were extracted for analysis and evaluation. The Chi-square test and I2 statistic were utilized to assess heterogeneity, while publication bias was examined through the construction of a funnel plot and the application of the Egger test. A total of 19 studies were included in this meta-analysis, including 2,354 patients with nasopharyngeal carcinoma. The results showed that immunotherapy had a good therapeutic effects on patients with nasopharyngeal carcinoma. The 0.5-3 year PFS of patients with nasopharyngeal carcinoma who received immunotherapy was significantly improved compared to the group who did not receive immunotherapy (OR: 1.87; 95% CI 1.22-2.85) and 0.5-3 year OS were also significantly improved (OR: 1.45; 95% CI 1.23-1.74). In terms of treatment-related adverse events (AEs), the incidence of ≥ grade 3 treatment-related AEs was 27% (95% CI 25-30%), and the incidence of combination therapy was higher than that of monotherapy. In the treatment of patients with nasopharyngeal carcinoma, immunotherapy has demonstrated superior efficacy compared to chemotherapy alone. Furthermore, the expression levels of EBV DNA and PD-L1 in the serum of patients significantly influence the therapeutic outcomes.
- 1 January 2025
- Published by ScopeMed in Medicine Science | International Medical Journal
- Vol. 14 (1) , 300
Open AccessEfficacy and safety of immunotherapy for nasopharyngeal carcinoma: A systematic review and meta-analysis
Cancer immunotherapy represents a more advanced and effective treatment modality compared to traditional therapies, playing a significant role in the management of patients with nasopharyngeal carcinoma. However, the efficacy of immunotherapy can be influenced by the 'double-edged sword' nature of the immune system and the individual differences among cancer patients. To assess the efficacy and safety of immunotherapy in patients with nasopharyngeal carcinoma, we conducted a systematic review and meta-analysis of published clinical studies. Clinical research literature related to nasopharyngeal carcinoma immunotherapy was searched in the PubMed, Web of Science, Embase, and Cochrane databases up until December 2010. The literature was screened rigorously according to predefined inclusion and exclusion criteria. Quality evaluation of the included studies was conducted using the Newcastle-Ottawa Scale (NOS), and studies meeting the inclusion criteria were extracted for analysis and evaluation. The Chi-square test and I2 statistic were utilized to assess heterogeneity, while publication bias was examined through the construction of a funnel plot and the application of the Egger test. A total of 19 studies were included in this meta-analysis, including 2,354 patients with nasopharyngeal carcinoma. The results showed that immunotherapy had a good therapeutic effects on patients with nasopharyngeal carcinoma. The 0.5-3 year PFS of patients with nasopharyngeal carcinoma who received immunotherapy was significantly improved compared to the group who did not receive immunotherapy (OR: 1.87; 95% CI 1.22-2.85) and 0.5-3 year OS were also significantly improved (OR: 1.45; 95% CI 1.23-1.74). In terms of treatment-related adverse events (AEs), the incidence of ≥ grade 3 treatment-related AEs was 27% (95% CI 25-30%), and the incidence of combination therapy was higher than that of monotherapy. In the treatment of patients with nasopharyngeal carcinoma, immunotherapy has demonstrated superior efficacy compared to chemotherapy alone. Furthermore, the expression levels of EBV DNA and PD-L1 in the serum of patients significantly influence the therapeutic outcomes.
- Open Access
- 27 November 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1475176
Long-term outcomes of induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
Background: Nasopharyngeal carcinoma (NPC) is a prevalent form of head and neck cancer, particularly in specific regions with a higher incidence. The optimal treatment strategy for locally advanced NPC (stage III and IVA, LA-NPC) involves various combinations of induction chemotherapy (IC), concurrent chemoradiotherapy (CCRT), and adjuvant chemotherapy (AC), each with distinct advantages. This one institutional study aims to retrospectively analysis the efficacy and clinical outcomes of IC with CCRT (IC+CCRT), CCRT with AC (CCRT+AC), and the comprehensive approach of IC followed by CCRT and subsequently AC (IC+CCRT+AC) in the management of LA-NPC.Materials and methods: A total of 352 LA-NPC patients were included: 173 accepted IC+CCRT, 60 received CCRT+AC, and 119 underwent IC+CCRT+AC. The primary endpoints including overall survival (OS) and progression-free survival (PFS), were assessed using the Kaplan-Meier method and log-rank test.Results: The median follow-up was 61.2 months (1-216 months). There was no significant difference in 5-year OS and PFS between IC group and no IC group, extending the observation time to 90 months, the OS and PFS were significantly better in IC group than no IC group (OS: 76% vs. 70%,P<0.05; PFS: 76% vs. 71%, P<0.05). Patients with 1, 2, or 3 cycles of IC had higher 5-year OS and PFS than those with more than 3 cycles (1-4 cycles IC OS: 89% vs. 87% vs. 88% vs. 79%, P<0.05; 1-4 cycles IC PFS: 87% vs. 85% vs. 85% vs. 70%, P<0.05). NP regimen demonstrated higher OS and PFS than TP, PF, and TPF regimens (OS: 95% vs. 82% vs. 85% vs. 71%, P<0.05; PFS: 93% vs. 83% vs. 81% vs. 80%, P<0.05). The 5-year OS and PFS were significantly better in AC group than no AC group (OS: 82% vs. 72%, P<0.05; PFS: 81% vs. 69%, P<0.05). In the AC group, there was no differential effect of chemotherapy cycles and chemotherapy regimens on patients’ OS and PFS. In the ThNh group, patients receiving IC+CCRT+AC had higher OS and PFS compared to those receiving IC+CCRT, with no significant difference in the rest (OS: 85% VS 66% P<0.05; PFS: 78% VS 62%, P<0.05).Conclusion: CCRT combined with IC or AC could benefit LA-NPC patients. The IC+CCRT +AC regimen was most beneficial for NPC patients with later T and N stages.
- 27 November 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1475176
Open AccessLong-term outcomes of induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
Background: Nasopharyngeal carcinoma (NPC) is a prevalent form of head and neck cancer, particularly in specific regions with a higher incidence. The optimal treatment strategy for locally advanced NPC (stage III and IVA, LA-NPC) involves various combinations of induction chemotherapy (IC), concurrent chemoradiotherapy (CCRT), and adjuvant chemotherapy (AC), each with distinct advantages. This one institutional study aims to retrospectively analysis the efficacy and clinical outcomes of IC with CCRT (IC+CCRT), CCRT with AC (CCRT+AC), and the comprehensive approach of IC followed by CCRT and subsequently AC (IC+CCRT+AC) in the management of LA-NPC.Materials and methods: A total of 352 LA-NPC patients were included: 173 accepted IC+CCRT, 60 received CCRT+AC, and 119 underwent IC+CCRT+AC. The primary endpoints including overall survival (OS) and progression-free survival (PFS), were assessed using the Kaplan-Meier method and log-rank test.Results: The median follow-up was 61.2 months (1-216 months). There was no significant difference in 5-year OS and PFS between IC group and no IC group, extending the observation time to 90 months, the OS and PFS were significantly better in IC group than no IC group (OS: 76% vs. 70%,P<0.05; PFS: 76% vs. 71%, P<0.05). Patients with 1, 2, or 3 cycles of IC had higher 5-year OS and PFS than those with more than 3 cycles (1-4 cycles IC OS: 89% vs. 87% vs. 88% vs. 79%, P<0.05; 1-4 cycles IC PFS: 87% vs. 85% vs. 85% vs. 70%, P<0.05). NP regimen demonstrated higher OS and PFS than TP, PF, and TPF regimens (OS: 95% vs. 82% vs. 85% vs. 71%, P<0.05; PFS: 93% vs. 83% vs. 81% vs. 80%, P<0.05). The 5-year OS and PFS were significantly better in AC group than no AC group (OS: 82% vs. 72%, P<0.05; PFS: 81% vs. 69%, P<0.05). In the AC group, there was no differential effect of chemotherapy cycles and chemotherapy regimens on patients’ OS and PFS. In the ThNh group, patients receiving IC+CCRT+AC had higher OS and PFS compared to those receiving IC+CCRT, with no significant difference in the rest (OS: 85% VS 66% P<0.05; PFS: 78% VS 62%, P<0.05).Conclusion: CCRT combined with IC or AC could benefit LA-NPC patients. The IC+CCRT +AC regimen was most beneficial for NPC patients with later T and N stages.
- 1 November 2022
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology (Versão em Português)
- Vol. 88, S42-S47
Incisão supraclavicular lateral em cirurgia de carcinoma papilífero unilateral de tireoide
- 1 November 2022
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology (Versão em Português)
- Vol. 88, S42-S47
Incisão supraclavicular lateral em cirurgia de carcinoma papilífero unilateral de tireoide
- Open Access
- 20 April 2021
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 88 (Suppl 1) , S42-S47
Application of lateral supraclavicular incision in unilateral thyroid papillary carcinoma surgery
- 20 April 2021
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 88 (Suppl 1) , S42-S47
Open AccessApplication of lateral supraclavicular incision in unilateral thyroid papillary carcinoma surgery
- Open Access
Two New Phenolic Glycosides from Viscum articulatum
Two new phenolic glycosides, 1-O-benzyl-[5-O-benzoyl-β-D-apiofuranosyl (1→2)]-β-D-glucopyranoside (1), and 4`-hydroxy-7,3`-dimethoxyflavan-5-O- β-D-gluco-pyranoside (2), together with nine known flavanones 3 - 11, have been isolated from the dried whole plants of Viscum articulatum.Their structures were identified by extensive spectral analysis, especially 2D NMR techniques. Compound 9 showed weak anti-HIV-1 activity.
Open AccessTwo New Phenolic Glycosides from Viscum articulatum
Two new phenolic glycosides, 1-O-benzyl-[5-O-benzoyl-β-D-apiofuranosyl (1→2)]-β-D-glucopyranoside (1), and 4`-hydroxy-7,3`-dimethoxyflavan-5-O- β-D-gluco-pyranoside (2), together with nine known flavanones 3 - 11, have been isolated from the dried whole plants of Viscum articulatum.Their structures were identified by extensive spectral analysis, especially 2D NMR techniques. Compound 9 showed weak anti-HIV-1 activity.